Search

Your search keyword '"Inanc, Nevsun"' showing total 288 results

Search Constraints

Start Over You searched for: Author "Inanc, Nevsun" Remove constraint Author: "Inanc, Nevsun"
288 results on '"Inanc, Nevsun"'

Search Results

1. Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study

2. The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation

3. Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study

5. A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry

8. The Sjögren's Working Group:The 2023 OMERACT meeting and provisional domain generation

9. The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation

10. A cross‐sectional study on activity impairment in primary Sjogren's syndrome.

11. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)

12. Exposure to air pollution as an environmental determinant of how Sjögren's disease is expressed at diagnosis

13. The Novel OMERACT Ultrasound Scoring System for Salivary Gland Changes in Patients With Sjögren Syndrome Is Associated With MRI and Salivary Flow Rates

16. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).

17. The Novel OMERACT Ultrasound Scoring System for Salivary Gland Changes in Patients With Sjögren Syndrome Is Associated With MRI and Salivary Flow Rates.

18. Influence of exposure to climate-related hazards in the phenotypic expression of primary Sjögren's syndrome

19. Unintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib

20. A cross‐sectional study on activity impairment in primary Sjogren's syndrome

22. Treatment of systemic sclerosis-associated digital ulcers: recommendations of the Turkish Society for Rheumatology

23. Mortality risk factors in primary Sjogren syndrome : a real-world, retrospective, cohort study

24. The provisional OMERACT ultrasonography score for giant cell arteritis

26. Characterisation of the coexistence between sarcoidosis and Sjögren's syndrome. Analysis of 43 patients

27. The provisional OMERACT ultrasonography score for giant cell arteritis

29. The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort

30. Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort

31. After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries

32. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

33. Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome

34. Development of a new ultrasound scoring system to evaluate glandular inflammation in Sjögren's syndrome:an OMERACT reliability exercise

35. The provisional OMERACT ultrasonography score for giant cell arteritis

36. Advanced glycation end products, a potential link between psoriasis and cardiovascular disease: A case-control study

37. After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.

40. Quality of life, disease activity and preferences for administration routes in rheumatoid arthritis: a multicentre, prospective, observational study

42. Post-COVID-19 syndrome in patients with primary Sjögren's syndrome after acute SARS-CoV-2 infection

43. Development of a new ultrasound scoring system to evaluate glandular inflammation in Sjögren’s syndrome: an OMERACT reliability exercise

45. Development of a new ultrasound scoring system to evaluate glandular inflammation in Sjögren's syndrome: an OMERACT reliability exercise.

46. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to countryʼs wealth?

49. Inequities in access to biologic and synthetic DMARDs across 46 European countries

Catalog

Books, media, physical & digital resources